• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Heart Lung . One-year outcomes of invasively managed acute coronary syndrome patients with COVID-19

tetano

Editor, Senior Moderator
Heart Lung


. 2022 Jan 21;52:159-164.
doi: 10.1016/j.hrtlng.2022.01.012. Online ahead of print.
One-year outcomes of invasively managed acute coronary syndrome patients with COVID-19


Tufan Çınar[SUP] 1 [/SUP], Faysal Şaylık[SUP] 2 [/SUP], Tayyar Akbulut[SUP] 2 [/SUP], Suha Asal[SUP] 3 [/SUP], Murat Selçuk[SUP] 3 [/SUP], Vedat Çiçek[SUP] 3 [/SUP], Şahhan Kılıç[SUP] 3 [/SUP], Ahmet Lütfullah Orhan[SUP] 3 [/SUP]



Affiliations

Abstract

Background: There is a limited data about the one-year outcomes of patients diagnosed with acute coronary syndrome (ACS) and coronavirus disease 2019 (COVID-19).
Objectives: To assess one-year mortality of invasively managed patients with ACS and COVID-19 compared to ACS patients without COVID-19.
Methods: In our investigation, we defined the study time period as April 30 through September 1, 2020. The control groups consisted of ACS patients without COVID-19 at the same time period and ACS patients prior to the pandemic, within the same months as those of the study. COVID-19 infection was confirmed in all participants utilizing real-time polymerase chain reaction testing.
Results: This investigation examined 721 ACS participants in total. Among the participants, 119 patients were diagnosed with ACS and COVID-19, while 149 were diagnosed with ACS and without COVID-19. The other 453 ACS participants were diagnosed before the outbreak of the pandemic, within the same months as those of the study. One-year mortality rates were higher in the ACS participants with COVID-19 than in the ACS participants without COVID-19 and the pre-COVID-19 ACS participants (21.3% vs. 6.5% vs. 6.9%, respectively). An ACS along with COVID-19 was the only independent predictor of one-year mortality (HR=2.902, 95%CI=1.211-6.824, P = 0.018). According to the Kaplan-Meier survival curves, patients with ACS and COVID-19 had a lower chance of survival in the short-term and one-year periods.
Conclusion: This is believed to be the first study to report that ACS patients with COVID-19 had higher one-year risk of mortality compared to ACS patients without COVID-19.

Keywords: Acute coronary syndrome; COVID-19; One-year mortality.
 
Back
Top Bottom